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Abstract
Background: Patients with Angelman syndrome (AS) are affected by severe intellectual disability with absence of
speech, distinctive dysmorphic craniofacial features, ataxia and a characteristic behavioral phenotype. AS is caused
by the lack of expression in neurons of the UBE3A gene, which is located in the 15q11.2-q13 imprinted region.
Functional loss of UBE3A is due to 15q11.2-q13 deletion, mutations in the UBE3A gene, paternal uniparental disomy
and genomic imprinting defects.
Case presentation: We report here two patients with clinical features of AS referred to our hospital for clinical
follow-up and genetic diagnosis. Methylation Specific-Multiplex Ligation-Dependent Probe Amplification (MS-MLPA)
of the 15q11.2-q13 region was carried out in our laboratory as the first diagnostic tool detecting two novel UBE3A
intragenic deletions. Subsequently, the MLPA P336-A2 kit was used to confirm and determine the size of the UBE3A
deletion in the two patients. A review of the clinical features of previously reported patients with whole UBE3A
gene or partial intragenic deletions is presented here together with these two new patients.
Conclusion: Although rare, UBE3A intragenic deletions may represent a small fraction of AS patients without a
genetic diagnosis. Testing for UBE3A intragenic exonic deletions should be performed in those AS patients with a
normal methylation pattern and no mutations in the UBE3A gene.
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Background
Angelman syndrome (AS) is a neurogenetic disorder
characterized by a severe intellectual disability with
absence of speech, distinctive dysmorphic craniofacial
features such as microcephaly with flat occiput and oc-
cipital groove, wide mouth, ataxia related neurological
problems and/or tremor in the limbs and seizures with
specific EEG pattern abnormalities that persist into
adulthood. The behavioural phenotype is characterized
by happy disposition, hyperactivity, attention deficit and
frequent disruption of sleep cycles. Other clinical
problems are gastrointestinal difficulties with feeding
problems, gastroesophageal reflux, constipation, scoli-
osis, and an increased sensitivity to heat. Its prevalence
is about 1/15000 births [1–3].
The cause of AS is the loss of function in neurons of
the ubiquitin protein ligase E6-AP (E6-Associated
Protein) encoded by the UBE3A gene, which is located
on chromosome 15q11.2-q13 region. This region in-
cludes a cluster of genes under imprinting control which
show differential expression depending on the parental
origin, in a tissue-specific manner. UBE3A shows a
specific expression of the maternal allele in neurons
while the paternal allele is silenced by the synthesis of
an antisense transcript from the SNURF-SNPRN gene
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(UBE3A-ATS). The absence of the specific maternal ex-
pression of UBE3A is the main cause of AS [4].
The functional loss of UBE3A in the maternal allele is
due to different genetic mechanisms: (i) deletion of the
region 15q11.2-q13 in 70–75% of patients, (ii) mutations
in the UBE3A gene in 10–15% of the patients, (iii) pater-
nal uniparental disomy in 1–3% of patients, and (iv)
genomic imprinting defects in 2–4% of the patients. The
genetic cause remains unknown in approximately 10% of
patients presenting clinical features characteristic of AS
[4, 5]. There are also some reports that describe a pro-
portion of AS patients who harbor microdeletions of the
UBE3A gene [6–10].
The UBE3A gene spans 120 kb of genomic DNA and
consists of 10 exons (NM_130838.1). The ubiquitin
protein ligase E6-AP encoded by the UBE3A gene is ne-
cessary for the ubiquitination of proteins targeted for
degradation. E6-AP belongs to the HECT (homologous
to E6-AP COOH terminus) class of E3 enzymes that
share a 40 kDa COOH-terminal catalytic domain. This
domain is encoded by exons 3–10 [11]. Exons 1 to 5 en-
code a steroid co-activation region which has several
LXXLL motifs that are known to be receptor interacting
motifs [12].
Mutations in the UBE3A gene are widely distributed
and have been detected throughout all regions of the
gene [13, 14]. Rare intragenic deletions and duplications
may represent a higher percentage of mutations than ex-
pected, because these alterations escape the routine
screening [15].
Here, we report two patients with AS who present two
novel intragenic deletions within the UBE3A gene.
Case presentation
Patient 1 is a 5 year-old girl born at 37 weeks of gesta-
tion. Birth weight was 2850 g. Neither perinatal prob-
lems nor hypotonia was reported. Initially, she didn’t
show feeding problems but when solid food was intro-
duced into her diet, she had difficulties to swallow.
Psychomotor development was delayed. She sat unsup-
ported at 9 months, walked independently at 24 months
and pronounced only two words which she lost later.
She came to the clinical geneticist when she was 2-year-
8-month old. Phenotypic features included relative
microcephaly (47 cm, −1.75 SD), small and wide-spaced
teeth and protruding tongue. Her weight was 12 Kg
(25th percentile) and her height was 80 cm (50th per-
centile). Neurological examination detected severe intel-
lectual disability, ataxia of gait, receptive and non-verbal
communication skills higher than verbal ones, hyperre-
flexia of the lower extremities, tremulous movement of
limbs and frequent drooling. She also had abnormal
sleep-wake cycles and by the age of 20 months she de-
veloped seizures. EEG showed generalized slow wave
activity with paroxysmal activity. The behavioural
phenotype included frequent laugher, happy demeanour,
easily excitable personality, hyperactive behaviour, atten-
tion deficit and exploration of objects throughout the
mouth. She also presented attraction to water and an in-
creased sensitivity to heat (Table 1).
Methylation PCR and UBE3A sequencing were carried
out in another centre with negative results. MS-MLPA
analysis was performed in our laboratory using a specific
kit, SALSA MS-MLPA ME028-B2 Prader Willi/Angelman,
(MRC Holland, Amsterdam, The Netherlands). This kit
contains 46 probes, 32 of which are specific for sequences
in or close to the PWS/AS critical region on 15q11.2-q13
which can be used to detect copy number changes in this
region. As a control for copy number changes, 14 probes
outside the PWS/AS region are included. Among the
PWS/AS specific probes, seven probes are methylation-
sensitive and contain a HhaI restriction site. Five probes
are located within the UBE3A gene corresponding to
exons 1, 2, 3, 4 and 9 (NM_130838.1). In this paper, we
use exon numbering according to NM_130838.1 sequence
which is the standard reference sequence for the UBE3A
gene where exons 1 to 10 correspond to exons 5b to 14 of
the NM_000462.3 sequence. MLPA was performed ac-
cording to manufacturer’s instructions (MRC Holland).
Amplification products were run on an ABI3130 analyser
(Applied Biosystems, California, USA) and analyzed using
the GeneMapper software (Applied Biosystems).
Methylation pattern of the 15q11.2-q13 region was
normal. However, dosage analysis showed a reduction
of 50% in the relative peak height of the probe corre-
sponding to UBE3A exon 2 while probes correspond-
ing to UBE3A exons 1, 3, 4 and 9 (NM_130838.1)
showed a normal diploid dosage (Fig. 1a). To confirm
the specific UBE3A exon 2 deletion the MLPA P336-
A2 kit (MRC Holland) was used. This kit contains 42
MLPA probes, including at least one probe for each
exon of the UBE3A gene.
A reduction of 50% in the relative peak height corre-
sponding to the probe located in the exon 2 was de-
tected while all other UBE3A exonic probes presented
normal dosage confirming that the deletion only in-
volved exon 2 (Fig. 1b). Parents testing showed that
deletion was de novo (Fig. 1b), although a germline mo-
saic cannot be excluded. In order to investigate in which
parental allele the deletion was originated, we used six
SNP located in intron 2: rs71418040, rs17114442,
rs28754450, rs57111857, rs757438 and rs61336305. All
of them were not informative so the maternal origin of
the deletion could not be confirmed.
Patient 2 is a 5 year-old girl born at term following an
uneventful pregnancy. Her birth weight was 3000 g. No
perinatal problems were reported but she was noted to
be hypotonic. She presented developmental delay.
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Table 1 Clinical data of patients with UBE3A intragenic deletions, following the clinical features of AS described by Williams et al.,
2006
Patient 1 Patient 2 Bürger,
et al., 2002
Boyes,
et al., 2006
Boyes,
et al., 2006
Calì, et al.,
2010
Beleza-Meireles,
et al., 2011
Piard,
et al., 2011
Piard,
et al., 2011
Genetics
Intragenic deletion Exon 2a Exons 9-10a Whole
UBE3A
Exons 8-16b Exons 8-16b Exon 8c Exons 5-12c Exons 6-12c Exons 6-12c
Predicted protein p.0? p.Arg765_
852del88
p. 0? p.0? p.0? p.Leu517Valfsa27 p.0? p.0? p.0?
Inheritance De novo De novo Maternal Maternal Maternal Maternal NA Maternal Maternal
Clinical data
Sex F F M F M M F F F
Weight at birth 2850 g 3000 g 2670 g 3200 g 3350 g 3370 g 3880 g NA NA
Perinatal problems – – NA NA NA – – NA NA
Age of sedestation (months) 9 8 12 18 21 18 NA 9 NA
Age of walk (months) 24 24 18 39 39 24 24 24 24
Consistent clinical features of AS (100% of the affected individuals)
Ataxia of gait + + + + + + + NA +
Frequent laugher/smiling + + + + + + + + +
Apparent happy demeanor + + NA + + NA + + +
Easily excitable personality + + NA NA NA NA NA NA NA
Hyperactive behaviour + + NA + + NA + NA +
Attention deficit + + NA NA NA NA NA NA NA
Hand flapping/stereotipies – + NA + NA NA + + +
Development delay + + + + + + + + +
Severe mental retardation + + + + + + + + +
Speech impairement + + + + + + + + +
Receptive and non-verbal
communication skills higher
than verbal ones
+ + + NA NA NA NA NA NA
Frequent clinical features of AS (more than 80% of the affected individuals)
Microcephaly Relative – + + + + – + +
Seizures + + NA + + – + + +
Abnormal EEG + + – + + + + + NA
Associatedclinical features of AS (20–80% of the affected individuals)
Hypotonia – + – + + + + NA NA
Feeding problems – – – NA NA NA + NA NA
Prognathia – + NA NA NA NA + NA NA
Flat Occiput – – NA NA NA NA + NA NA
Occipital groove – – NA NA NA NA NA NA NA
Hypopigmented skin, light
hair and eye color
– – – + + NA NA NA NA
Strabismus – – NA NA NA NA NA + +
Wide mouth – + – + NA NA NA + NA
Wide-spaced teeth + + – NA NA NA NA + +
Protruding tongue + – – + NA NA NA NA NA
Small hands and feet – – NA NA NA NA NA NA NA
Scoliosis – – NA NA + + NA NA +
Uplifted flexed arm position,
especially during
deambulation
– + NA NA NA NA NA NA NA
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Unsupported sedestation was achieved at 8 months and
independent walking at 24 months. Oral language was
limited to around 10 words.
Physical features of the patient included prognathia,
wide mouth and wide-spaced teeth. The neurological
manifestations included severe intellectual disability,
ataxia of gait, uplifted and flexed arm position during
deambulation, speech impairment, frequent drooling
and seizures. The EEG showed generalized slow wave
activity with paroxysmal activity. She didn’t present dis-
turbances of the sleep-wake cycle.
The behavioral traits included a happy demeanor with
smiling, laughing, hyperactive behavior, attention deficit,
hand flapping and chewing/mouthing behaviors. At the
age of the diagnosis, 5.6-year-old, her weight was 15 Kg
(10th percentile) and the head circumference was 48 cm
(−1.5 SD) (Table 1).
Initially, MLPA analysis was carried out using the
SALSA MLPA P064 Mental Retardation probemix-1 in
the Mother and Child Health Care Institute of Serbia. The
results showed a deletion of the exon 10 (NM_130838.1)
of the UBE3A gene (data not shown). Subsequently, a
DNA sample of the patient was sent to our laboratory for
further studies. MS-MLPA testing was performed and
showed a normal methylation pattern. However, a re-
duction of 50% in the relative peak height of the probe
corresponding to the UBE3A exon 9 was observed
while probes corresponding to UBE3A exons 1, 2, 3, 4
(NM_130838.1) showed a normal diploid dosage
(Fig. 1a). To confirm the UBE3A exon 9 and 10 dele-
tion and to determine whether the deletion expanded
to other exons, MLPA P336-A2 kit was used. MLPA
analysis confirmed the deletion only involving exon 9
and 10 (Fig. 1b). The genetic analysis in the parents
showed that the deletion encompassing exons 9 and 10
was de novo (Fig.1b). In patient 2, two SNPs in intron
9: rs573271880, rs17115485 and 1 SNP in exon 10:
rs10047992 were analyzed to investigate the parental
origin of the deletion. As in patient 1, we could not
confirm the maternal origin of the deletion.
Discussion and conclusions
Angelman syndrome is caused by the lack of expression
of the maternal copy in neurons of the UBE3A gene due
to four different molecular etiologies: Deletion of the
15q11.2-q13 region on the maternal chromosome, muta-
tions in the maternally-inherited copy of UBE3A, pater-
nal uniparental disomy for chromosome 15 and an
imprinting defect causing lack of expression of the ma-
ternal copy of UBE3A [16].
Genotype-phenotype correlations among molecular
subclasses have shown that deletion patients show a
more severe phenotype in all aspects of neurodevelop-
mental delay except for expressive language skills that
are extremely poor regardless of their molecular subclass
[17–21]. However, Mertz et al., 2014 report that children
with AS due to an UBE3A mutation or paternal unipa-
rental disomy present significantly better linguistic prop-
erties than deletion patients, in particular the expressive
area, where 6 out of 9 children with UBE3A mutation or
paternal uniparental disomy could use 2–7 words while
it was just the case in 3 out of 30 children with a
15q11.2-q13 deletion [22]. In addition, the deletion class
is the most severely affected regarding microcephaly,
seizures, relative hypopigmentation, motor difficulties
while paternal uniparental disomy and imprinting defect
individuals have better physical growth, have less move-
ment and ataxia abnormalities, and have a lower
Table 1 Clinical data of patients with UBE3A intragenic deletions, following the clinical features of AS described by Williams et al.,
2006 (Continued)
Patient 1 Patient 2 Bürger,
et al., 2002
Boyes,
et al., 2006
Boyes,
et al., 2006
Calì, et al.,
2010
Beleza-Meireles,
et al., 2011
Piard,
et al., 2011
Piard,
et al., 2011
Hyperreflexia of the lower
extremities
+ – NA + NA + NA NA NA
Tremolous movement
of limbs
+ – NA NA NA NA NA NA NA
Freqüent drooling + + NA NA NA + NA NA NA
Suck/swallowing disorders + – NA NA NA NA NA NA +
Abnormal sleep-wake cycle + – NA + + NA NA + +
Chewing/mouthing
behaviour
+ + NA NA NA NA NA NA NA
Atraction to/fascination with
water
+ – NA NA NA NA NA NA NA
Increased sensitivity to heat + – NA NA NA NA NA NA NA
F female, M male, + present, − absent, NA not available
aNomenclature exons 1–10 according to NM_130838.1
bNomenclature exons according to Kishino and Wagstaff, 1998; Yamamoto, et al., 1997
cNomenclature exons 1–14 according to NM_00462.3
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prevalence (but not absence) of seizures [18]. In
particular, individuals with deletions manifest higher
rates of epilepsy (90%, compared to 75% among indi-
viduals without deletion), earlier onset of seizures
(mean of age 1.9 years, compared with 6.3 years
among individuals without deletion) and may exhibit
a more severe electroencephalogram phenotype com-
pared to the other etiologies [23].
It has been suggested that AS patients carrying UBE3A
mutations show a phenotype somewhere in the middle
between deletion and paternal uniparental disomy car-
riers. They present higher incidences of seizures and
microcephaly, similar to deletion patients, while their
neurodevelopment delay is similar to paternal uniparental
disomy and imprinting defect patient carriers [18, 19]. A
revision of genotype-phenotype differences has been pub-
lished recently by La Salle et al. [24].
The patients presented in this report carry intragenic
UBE3A exonic deletions that affect the UBE3A open
reading frame. Exon 2 deletion in patient 1 is predicted
Fig. 1 Two intragenic deletions within the UBE3A gene (NM_130838.1) were identified by MLPA analysis in patients 1 and 2. a MS-MLPA analysis
with the ME028-B2 kit shows a normal methylation pattern and a heterozygous deletion of exon 2 in patient 1. A normal methylation pattern
and a heterozygous deletion of exon 9 were observed in patient 2. Red asterisks indicate the deleted exons. b MLPA analysis with the kit P336-A2
confirmed the deletion of exon 2 in patient 1 while a deletion involving exon 9 and 10 was observed in patient 2. In both cases the deletions
were de novo. Red asterisks indicate the deleted exons. c Summary of UBE3A intragenic deletions identified in this study and the literature. Exons
are depicted as grey boxes. Exons 1 to 5 constitute the steriod co-activation region and exons 3 to 10 constitute the HECT ligase domain, according to
Ramamoorthy and Nawaz et al., 2008. UBE3A deletions reported here and in the literature are shown as black bars
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to eliminate the start codon and consequently no pro-
tein will be produced (p.0?). Deletion of exons 9 and
10 in patient 2 is predicted to eliminate the last 88
aminoacids (p.Arg765_Leu852del88) disrupting the
ubiquitin ligase catalytic domain located at the 3′ end
of the protein (Fig. 1c).
So far, seven patients with whole UBE3A gene or par-
tial intragenic deletions have been reported (Fig. 1c). A
summary of their clinical features is presented in Table 1.
All deletions reported previously are also predicted to
affect the UBE3A open reading frame and create a pre-
mature stop codon at the beginning of the protein
(Table 1). Only patient 2 and the patient reported by
Cali et al., 2010 present exon deletions that would alter
the 3′ end of the UBE3A disrupting the ubiquitin ligase
activity of the protein.
All patients show the consistent clinical features of AS
except for patient 1 who does not present stereotypes.
This is surprising because stereotypes have been de-
scribed as a clinical feature often present in all patients
with AS since early in development. Microcephaly is
present in almost all patients (7 of nine patients) while
seizures are present in all except one (7 of eight patients
available). The high incidence of seizures and micro-
cephaly is in accordance to what has been reported
before by Lossie et al., 2001 and Moncla et al., 1999.
Associated clinical features show variability between pa-
tients. A comparison of AS patients with mutations and
intragenic deletions has not been reported before and
from our observations there are no differences between
the two groups.
In our laboratory, array Comparative Genomic
Hybridization (aCGH) is the first diagnostic tool in
neurodevelopmental disorders. Methylation Specific-
Multiplex Ligation-Dependent Probe Amplification
(MS-MLPA) of the 15q11.2-q13 region is carried out
when there is a strong clinical suspicion of Angelman
or Prader Willi syndrome. MS-MLPA analysis simul-
taneously assesses the methylation status and genomic
dosage changes at the 15q11.2-q13 region and can
confirm the diagnosis and identify the presence of a
causative deletion in 70% of cases. In the case of a
normal methylation pattern and if the clinical suspi-
cion remains high, sequence analysis of the UBE3A
gene is performed, as 10% of Angelman patients
harbor UBE3A mutations.
In addition, we propose here that the analysis of the
copy number variations within the UBE3A gene should
be taken into account, once the MS-MLPA test and the
sequencing of UBE3A have been carried out with a
negative result. Although rare, intragenic deletions may
account for a small proportion of AS patients without a
genetic diagnosis and if present, they have a recurrence
risk of up to 50%, depending on the carrier status of the
mother. In the two patients reported here the mutation
has appeared de novo but in the other intragenic
deletions previously reported they were transmitted
by healthy mothers to their affected children (Table 1).
Moreover, MLPA analysis of the UBE3A gene can be
used to confirm and precisely establish the size of an
intragenic deletion detected by MS-MLPA. The
SALSA MLPA kit P336-A2 UBE3A contains probes
for all coding exons of the UBE3A gene (exons 1–10,
NM_130838.1).
To date, few reports have evaluated the contribution
of exonic deletions to the spectrum of UBE3A muta-
tions. Here, we report two patients with AS who present
two novel intragenic deletions within the UBE3A gene
that together with those reported in the literature show
that UBE3A intragenic deletions may represent a small
fraction of AS patients. Testing for UBE3A intragenic
exonic deletions/duplications should be included in
those AS patients with a normal methylation pattern
and no mutations in the UBE3A gene.
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